News Summary
Former Louisiana Attorney General Charles C. Foti, Jr., is leading an investigation into the fairness of the proposed sale of Kronos Bio, Inc. to Concentra Biosciences, LLC. The transaction offers shareholders $0.57 in cash per share, along with a contingent value right. Kahn Swick & Foti, LLC is examining whether this payment sufficiently reflects the company’s valuation and is encouraging affected investors to discuss their legal rights without cost. The firm aims to uphold shareholder interests and ensure corporate fairness during the sale process.
New Orleans, LA – Former Louisiana Attorney General Charles C. Foti, Jr., Esq., is spearheading an investigation into the proposed sale of Kronos Bio, Inc. (NasdaqGS: KRON) to Concentra Biosciences, LLC. This transaction, which offers shareholders $0.57 in cash per share as well as a non-tradeable contingent value right, has raised questions regarding its fairness and adequacy for the company’s shareholders.
Kahn Swick & Foti, LLC (KSF), the law firm conducting the investigation, is scrutinizing whether the payment presented in the proposed transaction undervalues Kronos Bio, Inc. Their inquiry will assess the overall process that led to this valuation to determine if it was conducted fairly. Shareholders who think they may be impacted by this transaction are encouraged to contact KSF to discuss their legal rights, at no cost or obligation.
The transaction is structured as a tender offer, which typically requires prompt action from shareholders. KSF is actively seeking to inform affected investors of their options and potential next steps. Those interested can reach out to KSF Managing Partner Lewis S. Kahn via email or call the firm toll free to discuss details further.
Transaction Details
The proposed deal includes compensation of $0.57 cash per share held by shareholders of Kronos Bio. Additionally, shareholders will receive one non-tradeable contingent value right. Contingent value rights often pertain to additional benefits that shareholders might receive based on specific future events, which may include milestone achievements related to the company’s products or performance.
Investigation Objectives
The primary goal of KSF’s investigation is to determine if the offered payment reflects an accurate and fair valuation of Kronos Bio, Inc. By examining the circumstances surrounding the transaction, KSF aims to unveil any potential discrepancies or undervaluation that could affect shareholders adversely.
Contacting KSF
For shareholders of Kronos Bio, Inc. who wish to participate in this investigation, KSF has extended an invitation for discussions regarding their legal rights. There is no cost associated with these consultations. Interested parties can contact KSF through email at lewis.kahn@ksfcounsel.com or via their toll-free number 855-768-1857. More information about the investigation and KSF can be found on their official website.
Background on Kahn Swick & Foti, LLC
Kahn Swick & Foti, LLC is a legal firm with notable recognition, partially due to the involvement of Charles C. Foti, Jr., who has previously served as the Attorney General of Louisiana. This affiliation lends additional credibility to their investigations, particularly in corporate matters that require thorough legal scrutiny.
Location Information
KSF is headquartered at 1100 Poydras St., Suite 960, New Orleans, LA 70163, a central location that facilitates accessibility for clients and stakeholders involved in the ongoing investigation.
This continued investigation by KSF signifies the firm’s commitment to protecting shareholder interests and ensuring fair corporate practices in transactions involving public companies like Kronos Bio, Inc.
Deeper Dive: News & Info About This Topic
- Business Wire: Kronos Bio Investor Alert
- Wikipedia: Kronos Bio
- Business Wire: 2seventy Bio Investor Alert
- Google Search: 2seventy Bio
- Business Wire: AlloVir Investor Alert
- Google Scholar: AlloVir
- Business Wire: FuboTV Investor Alert
- Encyclopedia Britannica: FuboTV
- Business Wire: Intra-Cellular Therapies Investor Alert
- Google News: Intra-Cellular Therapies
